Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 4351 - 4400Blinatumomab in Relapsed or Refractory B-Cell Precursor ALL
On July 11, 2017, blinatumomab (Blincyto) was approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.1,2 Blinatumomab received accelerated approval in December 2014 for the treatment of Philadelphia chromosome (Ph)-negative...
Potential Effect of Excess Body Weight on Detection of Cervical Precancer
In a study reported in the Journal of Clinical Oncology, Clarke et al found that increasing body mass index (BMI) was associated with lower rates of cervical precancer diagnosis and higher rates of cervical cancer diagnosis. The investigators had hypothesized that increased body mass could decrease ...
Addition of Antibody-Drug Conjugate to Low-Intensity Chemotherapy in Older Patients With ALL
In a single-center phase II study reported in The Lancet Oncology, Kantarjian et al found that the addition of inotuzumab ozogamicin (Besponsa) to low-intensity chemotherapy produced promising outcomes in older patients with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic ...
Effects of Group Psychosocial Intervention on Body Image and Quality of Life in Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Esplen et al found that a group psychosocial intervention was effective in improving body image concerns and breast cancer–related quality of life among breast cancer survivors. Study Details In the study, 194 breast cancer survivors...
Is There a Benefit of Maintenance Bevacizumab During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer?
As reported by Aparicio et al in the Journal of Clinical Oncology, a French phase III trial (PRODIGE 9) showed no benefit of maintenance bevacizumab (Avastin) during postinduction chemotherapy-free intervals in metastatic colorectal cancer. Study Details In the open-label trial, 491 patients from ...
ASPIRE Trial: Final Overall Survival Results in Relapsed or Refractory Multiple Myeloma
The final overall survival results of the phase III ASPIRE trial indicate significant improvement with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) vs lenalidomide plus dexamethasone (Rd) in patients who had received one to three prior lines of therapy for multiple...
Obstetric and Neonatal Outcomes With Cancer Diagnosed During Pregnancy
As reported by de Haan et al in The Lancet Oncology, data from the International Network on Cancer, Infertility and Pregnancy (INCIP) registry indicate that use of chemotherapy during pregnancy has increased over a 20-year period, and that infants exposed to antenatal chemotherapy may be more...
Patients With Melanoma Treated With Anti–PD-1 Antibodies Beyond RECIST Progression
A pooled analysis by the U.S. Food and Drug Administration (FDA) has shown a benefit of treatment beyond progression, as defined by RECIST criteria, in many patients receiving anti–programmed cell death protein 1 (PD-1) antibodies for unresectable or metastatic melanoma. The analysis was ...
Racial Differences in Breast Cancer 21-Gene Recurrence Scores
In a study reported in the Journal of Clinical Oncology, Holowatyj et al found that among women with hormone receptor–positive, HER2-negative, node-negative invasive breast cancer, non-Hispanic black women had higher 21-gene recurrence scores at diagnosis vs non-Hispanic white women....
Multiple-Basket Study of Targeted Therapy for Advanced Solid Tumors
In a phase IIa multiple-basket study (MyPathway) reported in the Journal of Clinical Oncology, Hainsworth et al found that agents targeting specific molecular alterations produced responses in tumors outside of current labeling for the agents, with high response rates being observed in some tumor...
Patient-Reported Outcomes With Addition of Combination Treatment to ADT in Newly Diagnosed Metastatic Castration-Naive Prostate Cancer
As reported by Chi et al in The Lancet Oncology, the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) in the phase III LATITUDE trial was associated with improved patient-reported outcomes in patients with newly diagnosed metastatic castration-naive prostate cancer. The...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery in Advanced Ovarian Cancer
In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by van Driel et al, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery following neoadjuvant chemotherapy was associated with significantly improved recurrence-free and...
Germline BRCA Mutation and Outcomes in Young-Onset Breast Cancer
In the POSH study in the UK population reported in The Lancet Oncology, Copson et al found women with young-onset breast cancer who carry a germline BRCA mutation have survival similar to noncarriers, and BRCA-mutation carriers vs noncarriers with triple-negative breast cancer may have an early...
Role of Bone-Modifying Agents in Multiple Myeloma: ASCO Clinical Practice Guideline Update
As reported in the Journal of Clinical Oncology by Kenneth Anderson, MD, of Dana-Farber Cancer Institute, and colleagues, ASCO has issued a clinical practice guideline update on the role of bone-modifying agents in multiple myeloma. The update was informed by an expert panel systematic literature...
Cardiovascular Adverse Events and Multiple Myeloma Treatment
In a systematic review and meta-analysis reported in JAMA Oncology, Waxman et al found that any-grade and grade ≥ 3 cardiovascular adverse events occurred in 18.1% and 8.2% of patients receiving carfilzomib (Kyprolis) for multiple myeloma in clinical trials. Study Details The study involved...
Risk Prediction Model for Acute Kidney Injury After First Course of Cisplatin
As reported in the Journal of Clinical Oncology, Motwani et al have developed a predictive model for acute kidney injury following a first course of cisplatin that includes patient age, cisplatin dose, hypertension, and serum albumin level. Study Details The study involved data from 2,118...
Adjuvant Temozolomide in 1p/19q Non-codeleted Anaplastic Glioma
Interim results of the phase III CATNON trial (EORTC study 26053-22054) indicate a survival benefit of adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma. These findings were reported in The Lancet by Martin J. van den Bent, MD, of the Brain Tumour Centre at Erasmus MC Cancer...
Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer
In a Hong Kong study reported in The New England Journal of Medicine, K.C. Allen Chan, MBBS, PhD, MRCP, FRCPA, FHKCPath, FHMAM, of The Chinese University of Hong Kong, Department of Chemical Pathology, and colleagues found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is...
Nodal Stage Migration and Prognosis in Anal Cancer
In a study reported in The Lancet Oncology, Sekhar and colleagues found that the increasing proportion of lymph node–positive disease associated with enhanced detection techniques has led to nodal stage migration in anal cancer, which may reduce prognostic discrimination on the basis of lymph...
Reports From the Journal of Clinical Oncology
BREAST CANCER Survival in Metastatic Triple-Negative Breast Cancer Explored in Retrospective Study In a study reported in the Journal of Clinical Oncology, Stover et al found that cell-free (cf) DNA tumor fraction ≥ 10% was associated with worse survival in metastatic triple-negative breast...
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
As reported in the Journal of Clinical Oncology by Bryan J. Schneider, MD, of the University of Michigan, Ann Arbor, and colleagues, ASCO has endorsed the recently released American Society for Radiation Oncology (ASTRO) evidence-based guideline on stereotactic body radiotherapy (SBRT) in early...
Pembrolizumab in Advanced Urothelial Carcinoma
On May 18, 2017, pembrolizumab (Keytruda) was granted regular approval for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant...
Ceritinib in ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 26, 2017, ceritinib (Zykadia) was granted regular approval for treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by a U.S. Food and Drug Administration–approved test.1,2 In 2014, the drug received ...
Effect of TP53 Germline Variations on Outcomes in Pediatric B-Cell ALL
In a study reported in the Journal of Clinical Oncology, Qian et al found that loss-of-function germline TP53 variants increase the risk of childhood B-cell acute lymphoblastic leukemia (ALL), as well as the risk of poorer response to therapy and second malignancies. Study Details In the study,...
Barriers to Treatment in Limited-Stage Small Cell Lung Cancer
In a study reported in JAMA Oncology, Pezzi et al found that lack of health insurance, including Medicare and Medicaid, was associated with not receiving combined-modality therapy in limited-stage small cell lung cancer (SCLC). They also found that lack of insurance was associated with poorer...
Trastuzumab-dkst Approved as Biosimilar to Trastuzumab
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2017, trastuzumab-dkst (Ogivri) was...
Tumor-Specific T Cells and Response in Relapsed Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Bollard et al found that T cells with forced expression of dominant-negative transforming growth factor-β (TGF-β) receptor type 2 (DNRII) that targeted the Epstein Barr virus (EBV)-derived tumor antigens latent membrane proteins...
Triple Inhibitory Neoadjuvant Therapy in HER2-Positive, ER-Positive Breast Cancer
In an Italian phase II study reported in The Lancet Oncology, Gianni et al found that neoadjuvant therapy with the RB1 inhibitor palbociclib (Ibrance), estrogen receptor (ER) inhibitor fulvestrant (Faslodex), and human epidermal growth factor receptor 2 (HER2) inhibitors trastuzumab (Herceptin) and ...
Competing Causes of Death vs Primary Disease in Survivors of Head and Neck Cancer
In a study reported in JAMA Oncology, Simpson et al found that each year of survival in patients with primary head and neck cancer was associated with a 26% increased risk of death from competing causes, and that competing causes predominated after 5 years postdiagnosis. Study Details The study...
CTC Number May Be Marker of Improved Survival in Metastatic Castration-Resistant Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Heller et al identified two circulating tumor cell (CTC) markers that had high discriminatory ability for improved survival in metastatic castration-resistant prostate cancer. Study Details The study used individual patient data from 5...
Treatment Outcomes in Patients With Bone Metastasis From Advanced RCC
In a subgroup analysis of the phase III METEOR trial of advanced renal cell carcinoma (RCC) patients with with bone metastases, cabozantinib was associated with improved outcomes vs everolimus. The analysis was reported by Escudier et al in the Journal of Clinical Oncology. Study Details In the...
Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations May Affect Survival in Metastatic Triple-Negative Breast Cancer
In a study reported in the Journal of Clinical Oncology, Stover et al found that cell-free (cf) DNA tumor fraction ≥ 10% was associated with worse survival in metastatic triple-negative breast cancer, and that several somatic copy number alterations are enriched and prognostic in metastatic...
Study Finds Association Between Breast Implants and Risk of Anaplastic Large Cell Lymphoma
In a Dutch study reported in JAMA Oncology, de Boer et al found that breast implants were associated with an increased risk of anaplastic large cell lymphoma (ALCL) in the breast, although the absolute risk was small. Study Details In the study, all patients diagnosed with primary non-Hodgkin...
Passive Scattering Proton Therapy vs Intensity-Modulated Photon Radiotherapy for Locally Advanced NSCLC
In a study reported in the Journal of Clinical Oncology, Liao et al found that passive scattering proton radiotherapy (PSPT) improved heart—but not lung—radiation dose-volume indices vs intensity-modulated photon radiotherapy (IMRT) in patients with advanced non–small cell lung...
Brentuximab Vedotin Plus Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
A phase I/II trial has shown that the addition of brentuximab vedotin (Adcetris) to bendamustine is active in relapsed or refractory Hodgkin lymphoma. Study findings were reported in The Lancet Oncology by O’Connor et al. Study Details In the study, 64 patients with Hodgkin lymphoma and 1...
Out-of-Pocket Costs and Prescription Abandonment of Novel Oral Anticancer Agents
In a retrospective claims-based study reported in the Journal of Clinical Oncology, Doshi et al found that higher out-of-pocket costs were associated with increased rates of prescription abandonment for novel oral anticancer agents. Study Details The study involved data on 38,111 patients from...
PSA at 7 Months and Prognosis in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Chemotherapy
In a study reported in the Journal of Clinical Oncology, Harshman et al found that a prostate-specific antigen (PSA) level ≤ 0.2 ng/mL at 7 months after the start of androgen-deprivation therapy (ADT) was significantly associated with longer overall survival in metastatic...
PARP1 and Androgen Receptor Inhibition in Metastatic Castration-Resistant Prostate Cancer
In a phase II trial (NCI 9012) reported in the Journal of Clinical Oncology, Hussain et al found no benefit of adding PARP1 inhibition with veliparib to abiraterone (Zytiga) plus prednisone in patients with metastatic castration-resistant prostate cancer. ETS fusion status was not predictive of...
Durable Complete Responses After Discontinuation of Immunotherapy in Metastatic Melanoma
As reported in the Journal of Clinical Oncology by Robert and colleagues, a high proportion of patients with metastatic melanoma achieving complete response on pembrolizumab (Keytruda) in the phase Ib KEYNOTE-001 trial maintained complete response for prolonged durations after treatment...
Comparison of Chemoradiation Treatment Schedules in Locally Advanced Head and Neck Cancer
In an Indian phase III trial reported in the Journal of Clinical Oncology, Noronha and colleagues found that curative-intent adjuvant chemoradiotherapy with cisplatin at 100 mg/m2 every 3 weeks produced better locoregional control than cisplatin at 30 mg/m2 every week in patients with locally...
Everolimus in Previously Treated Thymoma and Thymic Carcinoma
In an Italian phase II study reported in the Journal of Clinical Oncology, Zucali et al found that everolimus was active in cisplatin-pretreated thymoma and thymic carcinoma; however, a high rate of fatal pneumonitis was observed. Study Details In the study, 51 patients with advanced/recurrent...
Bipolar Androgen Therapy After Progression on Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In a single-center phase II study reported in The Lancet Oncology, Teply et al found that bipolar androgen therapy can induce prostate-specific antigen (PSA) response and resensitization to enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer who progressed on...
Age-Associated Mortality Risk and BRAF V600E Status in Papillary Thyroid Cancer
In a study reported in the Journal of Clinical Oncology, Shen et al found evidence that BRAF V600E mutation status explains the long-recognized increased mortality risk associated with age at diagnosis in patients with papillary thyroid cancer. Study Details The study involved data from 2,638...
Cognitive Function After Hematopoietic Cell Transplantation for Hematologic Malignancy
In a prospective longitudinal study reported in the Journal of Clinical Oncology, Sharafeldin et al found that cognitive function after hematopoietic cell transplantation (HCT) for hematologic malignancy was impaired among those receiving myeloablative allogeneic HCT, with a delayed effect being...
Addition of Tumor-Treating Fields to Maintenance Temozolomide in Glioblastoma
Final results of a phase III trial reported by Stupp and colleagues in JAMA indicate that adding antimitotic treatment with tumor-treating fields to maintenance temozolomide is associated with improved progression-free and overall survival in patients with previously treated glioblastoma. The...
Radioiodine Treatment of Well-Differentiated Thyroid Cancer and Hematologic Malignancy Risk
In a study reported in the Journal of Clinical Oncology, Molenaar et al found that radioiodine treatment for well-differentiated thyroid cancer was associated with an increased risk of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) compared with thyroidectomy alone. Study Details ...
IMvigor211 Trial: Atezolizumab vs Chemotherapy in Platinum-Treated Advanced Urothelial Carcinoma
The phase III IMvigor211 trial showed no survival benefit for atezolizumab (Tecentriq) vs physician's choice of chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma with programmed death-ligand 1 (PD-L1) expression ≥ 5%. Findings were reported in The Lancet by...
Surveillance vs Metastasis-Directed Therapy in Recurrent Oligometastatic Prostate Cancer
In a Belgian phase II study reported in the Journal of Clinical Oncology, Ost et al found that androgen deprivation therapy (ADT)-free survival was prolonged with metastasis-directed therapy vs surveillance in recurrent oligometastatic prostate cancer. Study Details Sixty-two patients with...
Sequence of Postoperative Radiotherapy and Chemotherapy in Locally Advanced or Incompletely Resected NSCLC
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Francis et al found that receipt of adjuvant chemotherapy before vs concurrently with radiotherapy was associated with improved survival in patients with non–small cell lung cancer (NSCLC) found to have...
Association of Tumor-Infiltrating Lymphocytes With Prognosis in Breast Cancer Subtypes
In a study reported in The Lancet Oncology by Denkert et al, increased levels of tumor-infiltrating lymphocytes (TILs) in women receiving neoadjuvant chemotherapy were associated with improved prognosis in HER2-positive breast cancer and triple-negative breast cancer, but poorer outcome in luminal...
